Full-Time

Clinical Sales Specialist

Cardiac Therapies

Posted on 9/19/2025

Merit Medical Systems

Merit Medical Systems

1,001-5,000 employees

Manufactures disposable medical devices for interventions

Compensation Overview

$90k - $110k/yr

+ Bonus

Company Does Not Provide H1B Sponsorship

Riverside-San Bernardino-Ontario, CA, CA, USA

Hybrid

Candidate must reside in Southern California; travel 50-60% of the time.

Category
Sales & Account Management
Requirements
  • Candidate must reside in Southern California
  • This candidate will travel 50-60% of the time
  • Education and/or business experience equivalent to a related Bachelor's Degree preferably in the Cardiac Therapies Space
  • A minimum of five years of hands-on medical experience
  • Education and clinical experience equivalent to a Registered Nurse or Certified Cardiovascular or Radiology Technician preferred
  • Medical product sales and sales training experience preferred
  • Excellent communication skills and the ability to analyze feedback in a training environment to develop strategies to improve knowledge, skills, and abilities
  • A thorough understanding of training and development techniques
  • Good analytical skills and the ability to understand complex issues
  • Excellent organizational skills and the ability to coordinate large programs
  • Demonstrated computer skills preferably spreadsheets, word processing, database and other applicable software programs
Responsibilities
  • Provides clinical training to various groups such as Sales Representatives, Tech Teams, Merit employees, Cath lab and Radiology staff, and physicians on all Merit products in the Cardiac Therapies Product line
  • Answers clinical questions from doctors, technicians, sales representatives, etc.
  • Works with Sales Representatives in the field or customers to do evaluations and consultations or obtain complaint information
  • Follows up on previous product evaluations and conversions or complaints that require additional information
  • Establish relationships and builds confidence among lab staff, physicians, Sales Representatives, and customers
  • May ensure clinical details involving customer complaints are documented
  • May attend meetings to help determine which events/incidents require notification to regulatory authorities
  • Liaison between the lab/customers and Sales Representatives
  • May conduct assessment testing to ascertain the skill level and ability of those individuals being trained, and develop training curriculums and programs to improve knowledge, skill, and ability
  • Conducts ongoing staff training and provide clinical feedback to resolve customer related issues
  • Works in the field to support and train clinicians on the use of Merit products and to troubleshoot product related issues in the field
  • May assist with the roll out of new products, including educating the Sales Representatives on the features and benefits
  • Provides information on new technologies, procedures and changes in the medical device industry
  • May develop product training and procedural materials
  • May develop programs for labs to obtain CEU credits, in conjunction with an independent outside accredit firm
  • Works with the T.I.A. Department to improve existing products and the development of new products
  • May make presentations at Regional and National meetings regarding new products, procedures, and customer complaint requirements
  • Performs other related duties and tasks as required
Desired Qualifications
  • Education and clinical experience equivalent to a Registered Nurse or Certified Cardiovascular or Radiology Technician preferred
  • Medical product sales and sales training experience preferred
Merit Medical Systems

Merit Medical Systems

View

Merit Medical Systems develops, manufactures, and distributes proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. These one-time-use devices are used during procedures and supported by a global sales force and clinical team that provides training and support to hospitals. The company differentiates itself with a broad, multi-specialty product portfolio, an international footprint for manufacturing and distribution, and strong customer service and clinical support. Its goal is to transform patient care by delivering medical solutions that meet hospitals’ and patients’ needs worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

South Jordan, Utah

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • ViewPoint acquisition accretive by 2027 with OneMark sales projected to grow 20% annually.
  • OEM segment recovery to mid-single-digit growth in Q2 2026 after Asia-Pacific destocking.
  • Full-year 2026 guidance of 5.6% to 7.0% constant currency growth including $17-20M acquisitions.

What critics are saying

  • ViewPoint dilutes 2026 non-GAAP EPS by $0.05 with only $2-4M initial revenue contribution.
  • $15 million annual tariff assumption baked into guidance compresses gross margins permanently.
  • China weakness and volume-based purchasing pressure stall international growth below 5% constant currency target.

What makes Merit Medical Systems unique

  • Acquired ViewPoint Medical to triple oncology addressable market reach in breast cancer detection.
  • Record first-quarter non-GAAP operating margin of 19.7% despite 120 basis point tariff headwind.
  • Diversified portfolio across Cardiac, Endoscopy, and Oncology with integrated minimally invasive procedure solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Company News

The Associated Press
Apr 1st, 2026
Merit Medical acquires View Point Medical for $140M to expand breast cancer detection portfolio

Merit Medical Systems has acquired View Point Medical for approximately $140 million, expanding its therapeutic oncology portfolio. The California-based company manufactures the OneMark Detection Imaging System and tissue markers for breast and soft tissue tumour localisation. Merit paid $90 million in cash at closing, with two deferred payments of $25 million each scheduled over the next two years. The acquisition targets an estimated 1.3 million biopsy procedures annually in the United States. View Point's ultrasound-enhanced technology will complement Merit's existing SCOUT platform, offering physicians more localisation options during diagnostic biopsies and potentially reducing the need for separate pre-surgery procedures. For 2026, the acquisition is projected to contribute $2 million to $4 million in revenue. Merit expects revenue of $14 million to $16 million in 2027, with OneMark sales growing at least 20% annually.

PR Newswire
Mar 24th, 2026
Medtronic expands pain portfolio with FDA-cleared ViaVerte basivertebral nerve ablation system

Medtronic has entered into a distribution agreement with Merit Medical Systems to offer the ViaVerte system, an FDA-cleared basivertebral nerve ablation treatment for chronic vertebrogenic lower back pain. The minimally invasive, implant-free system features a physician-controlled steerable mechanism for precise nerve targeting. ViaVerte, which will be available later this year, offers same-day outpatient procedures for patients suffering from chronic lower back pain caused by damaged vertebral endplates. According to the American Chronic Pain Association, one in three Americans suffer from chronic pain. The agreement expands Medtronic's pain interventions portfolio, which includes spinal cord stimulation, vertebral augmentation and targeted drug delivery. Merit Medical currently supplies Medtronic with inflation syringes and steerable balloon catheters for vertebral compression fracture treatments.

Yahoo Finance
Mar 16th, 2026
Merit Medical launches Resilience esophageal stent with anti-migration design for cancer treatment

Merit Medical Systems has launched the Resilience Through-the-Scope Esophageal Stent in the US, designed to treat esophageal fistulas and strictures caused by malignant tumours. The stent features proprietary anti-migration flanges to prevent movement and is designed to demonstrate the greatest migration resistance amongst currently available TTS stents. A single-handed deployment system enables precise placement, whilst unique sizing options — 14mm x 50mm, 17mm x 50mm, and 20mm x 50mm — address various clinical needs unavailable elsewhere. Esophageal cancer is the sixth most common cause of cancer deaths globally. The new stent joins Merit's endoscopy portfolio, offering physicians enhanced control for treating patients experiencing difficulty swallowing, regurgitation and chest pain caused by esophageal narrowing.

Yahoo Finance
Mar 16th, 2026
Wells Fargo downgrade triggers institutional selling in Merit Medical Systems despite $1.61B revenue guidance

Merit Medical Systems has faced pressure following a Wells Fargo downgrade and subsequent institutional selling, creating a disconnect between market sentiment and the company's fundamentals. The medical device supplier maintains solid operations despite the negative mood shift. Merit recently issued 2026 revenue guidance of $1.610 billion to $1.630 billion, implying mid-single-digit growth despite current headwinds including delayed WRAPSODY CIE reimbursement and higher operating expenses. The company's narrative projects $1.8 billion revenue and $197.2 million earnings by 2028, requiring 7% annual revenue growth. Key risks include continued weakness in China and volume-based purchasing pressure. Simply Wall St Community members currently value the stock between $82.26 and $103.55, suggesting potential upside of up to 48% from current levels.

Yahoo Finance
Feb 26th, 2026
Merit Medical Q4 earnings beat estimates as revenues rise 11% to $394M

Merit Medical Systems reported fourth-quarter 2025 adjusted earnings per share of $1.04, up 12% year over year and beating the Zacks Consensus Estimate by 8.3%. GAAP EPS was 63 cents, up 37% year over year. Fourth-quarter revenues reached $393.9 million, up 11% on a reported basis and topping the consensus estimate by 0.8%. At constant exchange rate, revenues increased 10%, with organic growth of 6.8%. For the full year, adjusted EPS improved 11% to $3.83, whilst total revenues rose 12% to $1.52 billion on a reported basis. US sales grew 11.6% to $238.2 million, and international sales increased 9.9% to $155.7 million. The Cardiovascular segment, which accounts for the majority of revenue, grew 11% to $373.9 million.

INACTIVE